Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

1.24

Mkt cap

15M

Volume

80K

High

1.27

P/E Ratio

-0.60

52-wk high

7.33

Low

1.21

Div yield

N/A

52-wk low

1.10

In Tuesday's pre-market session, several healthcare stocks showed significant movement. Regulus Therapeutics led the gainers with an 84.8% increase, while Renalytix faced the largest drop among the losers, declining by 27.2%. Notably, Bioventus and CytomX Therapeutics released their Q4 earnings, influencing their stock prices.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 1:06 pm

NRx Pharmaceuticals is considering a reverse stock split to comply with Nasdaq listing requirements. This action may also involve a change in the company's name and CUSIP number. Additionally, the company has hired attorneys to address and prevent naked short positions in its securities.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:57 am

NRx Pharmaceuticals, Inc. (NRXP) and its subsidiary HOPE Therapeutics have completed a Memorandum of Understanding with Conversio Health and established a partnership with Nephron Pharmaceuticals for the distribution of IV Ketamine. This collaboration aims to provide a consistent supply of high-quality, FDA- and DEA-compliant IV ketamine to patients and clinics nationwide. The company is preparing for the initial sale of ketamine by the end of March 2024 and plans to file a New Drug Application (NDA) for HTX-100, with a potential launch in early 2025.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 12:36 pm

In Friday's after-market session, several healthcare stocks showed notable movements. Talphera's shares surged by 15.6% following its Q4 earnings report. Other gainers included Genelux, Estrella Immunopharma, Inspire Veterinary, NRX Pharmaceuticals, and Fortrea Holdings with increases ranging from 5.02% to 10.06%. Conversely, Atara Biotherapeutics led the losers, dropping by 9.4%, followed by declines in ProKidney, Mira Pharmaceuticals, Yield10 Bioscience, GeneDx Hldgs, and Envoy Medical.

Portfolio Pulse from Benzinga Insights

March 08, 2024 | 9:31 pm

Nrx Pharmaceuticals has entered into a definitive purchase agreement to sell 2.7 million shares at $0.38 per share, causing its stock to trade higher.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 4:00 pm

NRx Pharmaceuticals has entered into a definitive purchase agreement with an existing investor for the sale of 2.7 million shares at $0.38 per share, raising approximately $1.0 million. This represents a 26.7% premium over the recent share offering. The deal also includes a 5-year warrant with a $0.40 per share strike price. The funds will support the company's development pipeline, including projects on Suicidal Depression, Suicidal Bipolar Depression, and Chronic Pain, in addition to general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:33 pm

U.S. stocks showed mixed performance with the Dow Jones falling by 0.35% and the NASDAQ rising by 0.28%. J.M. Smucker reported better-than-expected earnings, while Janux Therapeutics, Hims & Hers Health, and Viking Therapeutics saw significant stock price increases. Conversely, Minerva Neurosciences, Thoughtworks Holding, and NRx Pharmaceuticals experienced notable declines. Oil and gold prices saw slight increases.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 7:32 pm

Health care stocks experienced significant movements in Tuesday's intraday session, with notable gainers including Janux Therapeutics, Viking Therapeutics, and CytomX Therapeutics, among others. Losers for the day included Minerva Neurosciences, NRX Pharmaceuticals, and Calidi Biotherapeutics. Factors influencing these movements include recent earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 5:31 pm

Macy's Inc announced mixed Q4 results and plans to close 150 stores as part of a new growth strategy. U.S. stocks traded mixed, with the Dow Jones falling and NASDAQ rising. Janux Therapeutics, Hims & Hers Health, and Viking Therapeutics saw significant stock increases, while Minerva Neurosciences, Thoughtworks Holding, and NRx Pharmaceuticals experienced declines. Oil prices rose by 1%, and gold increased slightly.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 5:24 pm

Nasdaq rose by 50 points as Lowe's Companies Inc (LOW) reported better-than-expected Q4 results, with sales of $18.60 billion and EPS of $1.77. Lowe's anticipates FY24 revenue of $84-$85 billion and adjusted EPS of $12.00-$12.30. Janux Therapeutics (JANX), Infobird Co. (IFBD), and Viking Therapeutics (VKTX) saw significant stock increases due to positive clinical data and market volatility. Conversely, Minerva Neurosciences (NERV), Thoughtworks Holding (TWKS), and NRx Pharmaceuticals (NRXP) experienced substantial declines due to regulatory setbacks and disappointing financial results.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 2:42 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.